Trial Profile
A Randomized Phase I/II, Multi-Center, Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs PR 104 (Primary) ; Sorafenib
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Proacta
- 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 24 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Nov 2009 New source identified and integrated (Moores UCSD Cancer Center; 6845)